Precision BioSciences to present data at AASLD on PBGENE-HBV for CHB

Precision BioSciences announced that the company will present late-breaking data at the American Association for the Study of Liver Diseases’ or AASLD, The Liver Meeting being held in Boston, MA. The poster highlights preclinical data demonstrating PBGENE-HBV’s ability to eliminate cccDNA and inactivate hepatitis B virus,HBV. DNA, meriting further investigation as a potentially curative treatment for chronic hepatitis B or CHB. The late-breaking poster, titled “Preclinical efficacy and safety of ARCUS-POL nucleases for chronic hepatitis B: a potentially curative strategy”, will be on display on Monday, November 13 from 1:00 PM – 2:00 PM ET in Hall C. Based on data to be presented today in a non-human primate model of HBV, the ARCUS nuclease was well tolerated and demonstrated up to 99% viral engagement which is defined as the percent of viral DNA that is either eliminated or inactivated following treatment.. “Eliminating cccDNA and inactivating integrated HBV DNA are both essential to drive a durable loss of viral markers and achieve a functional cure for HBV,” said Jeff Smith, Ph.D., Co-Founder and Chief Research Officer of Precision BioSciences. “In the data presented today, we have demonstrated the ability of our PBGENE-HBV program to durably achieve a near-complete reduction across these viral markers including HBsAg, hepatitis B e-antigen , HBV DNA and HBV RNA. We believe that these data further validate our HBV program and enable us to progress the final clinical candidate toward anticipated clinical trial application and/or investigational new drug application in 2024.”